Event-Driven Stocks

MIRA PHARMACEUTICALS, INC.

MIRANasdaq

Healthcare · Pharmaceutical Preparations · FL · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs2 good1 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22
Revenue
Operating income
Net income−$10.4M−$7.9M−$12.0M−$7.1M
Total assets$11.1M$2.9M$4.9M$858,074
Total liabilities$702,068$723,349$558,097$1.5M
Equity$10.4M$2.2M$4.4M−$596,232
EPS (diluted)$-1.35$-0.51$-0.85$-0.40
Shares out.16.8M14.8M14.8M13.3M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
Net margin
Return on equity
−100.5%
Return on assets
−94.1%
Return on capital (ROCE)
Liabilities / assets
6.3%
Debt / equity
0.07×
Book value / share
$0.62
Revenue growth (YoY)
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
52.1%clean
Piotroski F-Score
4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
50
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

1 warning2 good
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
3 acquisitions1 disposalsnet +2.7M shares · last 4
InsiderDateTypeSharesPrice
Shekhat Denil NanjiDirectorOct 1, 2025Grant22,378$1.35
Aminov ErezOfficer — Chief Executive OfficerOct 1, 2025Grant2.7M
Aminov ErezOfficer — Chief Executive OfficerAug 29, 2025Grant62,500$1.37
Aminov ErezOfficer — Chief Executive OfficerNov 19, 2024Sell55,410$1.39

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026408,1573.7-1.0%
Apr 30, 2026412,2492.3+8.9%
Apr 15, 2026378,4942.5-13.4%
Mar 31, 2026437,0322.4+31.6%
Mar 13, 2026332,1232.0-32.1%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.